Metformin Accord

Metformin Hydrochloride, the active ingredient in Metformin Accord, is a Biguanide presented as an oral dosage form for oral use. It decreases hepatic glucose production and improves peripheral insulin sensitivity to manage type 2 diabetes mellitus in adults.

GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Accord belongs to the biguanide class and is used to improve glycaemic control in disorders of glucose metabolism.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Impaired glucose tolerance: reduces the risk of progression to overt diabetes. Prediabetes: enhances insulin sensitivity and helps maintain normal glucose homeostasis.

Metformin Accord may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: transient after dosing. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes. - Hypoglycaemia: when combined with other glucose‑lowering agents. - Pancreatitis: rare inflammation of the pancreas. - Anemia: due to reduced red blood cell production.

When prescribing Metformin Accord, clinicians should consider several safety measures.

Renal function monitoring: assess creatinine clearance before initiation and periodically. Hepatic function assessment: avoid use in patients with significant liver disease. Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. Vitamin B12 surveillance: monitor levels during long‑term therapy. Avoid in severe heart failure: increased risk of metabolic complications. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Accord can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis. - Cimetidine: increases metformin plasma concentrations. - Alcohol: enhances risk of lactic acidosis. - Carbamazepine: reduces metformin effectiveness. - Rifampicin: may lower metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors: can affect renal function, influencing metformin clearance. - Diuretics: may alter fluid balance and renal excretion. - Warfarin: potential for altered anticoagulation control. - Digoxin: monitor for changes in serum levels.